MedTrace Logo

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

NCT01002664 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2018-08-02

No results posted yet for this study

Summary

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Conditions

  • Lower Urinary Tract Symptoms
  • Benign Prostatic Hyperplasia

Interventions

DRUG

MCS-2

30 mg/day (two 15 mg capsules) Qd for 12 weeks

DRUG

Placebo

2 soft-gel placebo capsules Qd for 12 weeks

Sponsors & Collaborators

  • Health Ever Bio-Tech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yeong-Shiau Pu, MD PhD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01002664 on ClinicalTrials.gov